| ISSN |
2150-5349 (online) |
| Open Access |
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2017. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Observational Study |
| Article Title |
Interferon-free treatments in patients with hepatitis C genotype 1-4 infections in a real-world setting
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Huascar Ramos, Pedro Linares, Ester Badia, Isabel Martín, Judith Gómez, Carolina Almohalla, Francisco Jorquera, Sara Calvo, Isidro García, Pilar Conde, Begoña Álvarez, Guillermo Karpman, Sara Lorenzo, Visitación Gozalo, Mónica Vásquez, Diana Joao, Marina de Benito, Lourdes Ruiz, Felipe Jiménez, Federico Sáez-Royuela and Asociación Castellano y Leonesa de Hepatología (ACyLHE). |
| Funding Agency and Grant Number |
| Funding Agency |
Grant Number |
| Fundación Burgos por la Investigación de la Salud and Gerencia Regional de Salud de Castilla y León |
BUO/06/15 |
|
| Corresponding Author |
Federico Sáez-Royuela, MD, PhD, Department of Gastroenterology and Hepatology, Hospital Universitario de Burgos, Avda, Islas Baleares 3, 09006 Burgos, Spain. fsroyuela@gmail.com |
| Key Words |
Hepatitis C virus infection; Genotype 1-4; Real world treatment; Direct-acting antiviral agents |
| Core Tip |
Our study analyzes the hepatitis C virus (HCV) most common genotypes treatment and all the possible combinations with direct-acting antiviral agents which are nowadays available in our country. We have found sustained virological response rates up to 90%, even in genotypes 1 and 3. The current study analyzes HCV RNA after 4 wk of treatment and 12 and 24 wk after the end of the treatment, as well as the adverse events. We analyze, separately, the patients who meet or do not meet the inclusion criteria of a clinical trial, finding that in this last group the response is lower. |
| Publish Date |
2017-05-04 08:16 |
| Citation |
Ramos H, Linares P, Badia E, Martín I, Gómez J, Almohalla C, Jorquera F, Calvo S, García I, Conde P, Álvarez B, Karpman G, Lorenzo S, Gozalo V, Vásquez M, Joao D, de Benito M, Ruiz L, Jiménez F, Sáez-Royuela F; Asociación Castellano y Leonesa de Hepatología (ACyLHE). Interferon-free treatments in patients with hepatitis C genotype 1-4 infections in a real-world setting. World J Gastrointest Pharmacol Ther 2017; 8(2): 137-146 |
| URL |
http://www.wjgnet.com/2150-5349/full/v8/i2/137.htm |
| DOI |
http://dx.doi.org/10.4292/wjgpt.v8.i2.137 |
